Brief: Lipocine Announces Positive Week 52 Results From LPCN 1148 Phase 2 Study In Patients With Cirrhosis

Lipocine

28/03/2024 10:31

March 28 (Reuters) - Lipocine Inc  LPCN.O :
    * LIPOCINE ANNOUNCES POSITIVE WEEK 52 RESULTS FROM LPCN 1148
PHASE
2 STUDY IN PATIENTS WITH CIRRHOSIS
    * LIPOCINE INC -     LPCN 1148 WAS WELL-TOLERATED, WITH AE
RATES
AND SEVERITIES SIMILAR TO PLACEBO.
    * LIPOCINE INC -     MET PRIMARY AND HEPATIC ENCEPHALOPATHY
(HE)
ENDPOINTS IN PHASE 2 STUDY
    * LIPOCINE - THERE WERE TWO DEATHS REPORTED IN
PLACEBO-TREATED
PARTICIPANTS AND ONE IN LPCN 1148-TREATED PARTICIPANTS DURING
THE STUDY
    * LIPOCINE - PARTICIPANTS ON LPCN 1148 WERE HOSPITALIZED FOR
FEWER
TOTAL DAYS WITH SHORTER HOSPITAL STAYS

Source text for Eikon:  ID:n0001493152-24-011600 
Further company coverage:  LPCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))